Earnings Releases·Nov 5, 2026, 6:03 AM ET

Haemonetics — Second Quarter Fiscal 2027 Earnings Summary

Reported Q2 fiscal 2027 revenue of $357.8 million (+9.3% YoY) and GAAP net income of $46.3 million ($1.00 EPS), up from $38.7 million ($0.81 EPS) in the prior year period.
Raised full-year fiscal 2027 revenue growth guidance to 8–11% (from 5–8%) and organic revenue growth to 6–9% (from 4–7%), while narrowing adjusted operating margin expansion guidance to 0–50 basis points.
Apheresis segment drove growth with $204.8 million in revenue (+12.6% YoY), while MedSurg posted $153.0 million (+5.1% YoY), supported by the expansion of the CSL relationship and innovation milestones.
Generated $103.8 million in free cash flow for the quarter (+$15.1 million YoY), with year-to-date free cash flow at $142.9 million and long-term debt reduced to $1,114.1 million.